.jpeg){kind=spacer}
JP Nadda, Union Minister for Health & Family Welfare and Chemicals & Fertilizers, had a one-on-one discussion with H.E. Dmitry Nikolaevich Patrushev, Deputy Prime Minister of the Russian Federation, at Nirman Bhavan, New Delhi.
Moderna has conveyed that the primary immunogenicity data for the 2025-2026 formula of mNEXSPIKE, the mRNA COVID-19 vaccine of their choice to the LP.8.1 variant of SARS-CoV-2, is in the positive range.
The revolutionary change that could dramatically impact the prevention of HIV may well hinge on how fast Indian regulators accept the proposal. Gilead Sciences, a US-based company, gave no-royalty licenses to four Indian firms
AbbVie announced that it has officially submitted a NDA to the USFDA for tavapadon, a next generation selective dopamine D1/D5 receptor partial agonist created to be taken once daily for oral administration for the treatment of Parkinson's...
Pfizer Inc. is poised to highlight key advances from its oncology portfolio at the European Society for Medical Oncology (ESMO) Congress 2025, which runs from October 17 to 21 in Berlin. With over 45 abstracts, including 11 oral and mini oral...
Illumina Inc. has announced global partnerships with top pharmaceutical companies for companion diagnostics (CDx) on Illumina’s TruSight Oncology (TSO) Comprehensive genomic profiling test. The collaboration focuses on KRAS alterations...
AbbVie, a global biopharmaceutical leader, hosted the National Conclave on World Retina Day at the India Habitat Centre, Delhi, which focused on Diabetic Macular Edema
Poly Medicure Ltd., a prominent medical device manufacturing company in India, has made public the signing of a conclusive agreement for the purchase of Medistream SA, the parent of Citieffe SRL
Glenmark Specialty S.A. (GSSA), a fully owned subsidiary of Glenmark Pharmaceuticals Ltd. (Glenmark), announced that it and Hengrui Pharma have signed an exclusive license and collaboration agreement for the next-generation HER2-targeting antibody
The US FDA has granted fast track designation to Sanofi’s SAR446268, an experimental gene therapy for myotonic dystrophy type 1 (DM1). This rare progressive neuromuscular disease affects about 1 in 2300 people globally, and has no approved...
.jpg)
.jpg)
, CDSCO.jpg)